CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

被引：1

作者：

Xuan, Jiachen ^{[1
,2
]}

Pearson, Richard B. ^{[1
,2
,3
,4
]}

Sanij, Elaine ^{[1
,2
,5
]}

机构：

[1] Peter MacCallum Canc Ctr, Canc Res Div, Melbourne, Vic, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia

[3] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia

[4] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic, Australia

[5] Univ Melbourne, Dept Clin Pathol, Parkville, Vic, Australia

来源：

MOLECULAR & CELLULAR ONCOLOGY | 2020年 / 7卷 / 06期

基金：

英国医学研究理事会;

关键词：

Ovarian cancer; PARPI; drug resistance; CX-5461;

D O I：

10.1080/23723556.2020.1805256

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.

引用

页数：3

共 50 条

[31] The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
Yan, Shunfei
Xuan, Jiachen
Brajanovski, Natalie
Tancock, Madeleine R. C.
Madhamshettiwar, Piyush B.
Simpson, Kaylene J.
Ellis, Sarah
Kang, Jian
Cullinane, Carleen
Sheppard, Karen E.
Hannan, Katherine M.
Hannan, Ross D.
Sanij, Elaine
Pearson, Richard B.
Chan, Keefe T.
BRITISH JOURNAL OF CANCER, 2021, 124 (03) : 616 - 627
[32] Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer
Huang, Yuhan
Liu, Chen
You, Lixin
Li, Xi
Chen, Gang
Fan, Junpeng
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2023, 27 (05) : 634 - 649
[33] ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistant Ovarian Cancer
McMellen, Alexandra
REPRODUCTIVE SCIENCES, 2022, 29 (SUPPL 1) : 145 - 145
[34] Investigation of the JAK/STAT signaling pathway in chemotherapy and PARP inhibitor resistant ovarian cancer
Rodman, Esther
Emch, Michael
Bruinsma, Elizabeth
Hou, Xiaonan
Kaufmann, Scott
Weroha, Saravut J.
Hawse, John
CANCER RESEARCH, 2023, 83 (07)
[35] PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Baghmar, S.
Agarwal, A.
Gauda, C.
Qureshi, S.
Malik, P. S.
Vaibhav, V.
ANNALS OF ONCOLOGY, 2019, 30
[36] Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability
Whalen, Jenna M.
Earley, Jillian
Wisniewski, Christi
Mercurio, Arthur M.
Cantor, Sharon B.
NATURE CANCER, 2025, 6 (02) : 278 - 291
[37] EHMT and PARP Inhibition Effectively Reduces Tumor Progression in a Unique PARP Inhibitor Resistant Syngeneic Ovarian Cancer Model
Watson, Zachary L.
Nguyen, Lily
Woodruff, Elizabeth
Chuong, Edward
Corr, Bradley
Gibaja, Veronica
Behbakht, Kian
Bitler, Benjamin G.
REPRODUCTIVE SCIENCES, 2022, 29 (SUPPL 1) : 230 - 230
[38] Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer.
Shah, Payal D.
Zarrin, Haley
Wethington, Stephanie
Latif, Nawar
Martin, Lainie
Rodriguez, Diego
Elkins, Katie
Giuntoli, Robert
Burger, Robert
Tanyi, Janos
Morgan, Mark
Domchek, Susan M.
Gailliard, Stephanie
Armstrong, Deborah K.
Simpkins, Fiona
CLINICAL CANCER RESEARCH, 2020, 26 (13) : 75 - 75
[39] A comparison of the activity of the quadruplex-targeting experimental drugs QN-302 and CX-5461 (pidnarulex) in wild-type and gemcitabine-resistant pancreatic cancer cell lines
Ahmed, Ahmed
Arshad, Tariq
Neidle, Stephen
CANCER RESEARCH, 2023, 83 (07)
[40] Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Funingana, Ionut-Gabriel
Reinius, Marika A., V
Petrillo, Angelica
Ang, Joo Ern
Brenton, James D.
SEMINARS IN CANCER BIOLOGY, 2021, 77 : 67 - 82

← 1 2 3 4 5 →